Developing an antibody-binding protein cage as a molecular recognition drug modular nanoplatform

被引:71
作者
Kang, Hyo Jin [2 ,3 ]
Kang, Young Ji [1 ]
Lee, Young-Mi [2 ,3 ]
Shin, Hyun-Hee [1 ]
Chung, Sang J. [2 ,3 ]
Kang, Sebyung [1 ]
机构
[1] UNIST, Sch Nanobiosci & Chem Engn, Ulsan 689798, South Korea
[2] KRIBB, BioNanotechnol Res Ctr, Taejon 305806, South Korea
[3] Korea Univ Sci & Technol UST, Nanobiotechnol Div, Taejon 305806, South Korea
关键词
Protein cages; Antibody-binding; Fc-binding peptide; Delivery platform; Molecular recognition; VIRUS-LIKE PARTICLES; MACROMOLECULAR THERAPEUTICS; CANCER-THERAPY; DELIVERY; IMMOBILIZATION; PLATFORM; NANOTECHNOLOGY; NANOPARTICLES; SURFACE; DESIGN;
D O I
10.1016/j.biomaterials.2012.03.055
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
We genetically introduced the Fc-binding peptide (FcBP) into the loop of a self-assembled protein cage, ferritin, constituting four-fold symmetry at the surface to use it as a modular delivery nanoplatform. FcBP-presenting ferritin (FcBP-ferritin) formed very stable non-covalent complexes with both human and rabbit IgGs through the simple molecular recognition between the Fc region of the antibodies and the Fc-binding peptide clusters inserted onto the surface of FcBP-ferritin. This approach realized orientation-controlled display of antibodies on the surfaces of the protein cages simply by mixing without any complicated chemical conjugation. Using trastuzumab, a human anti-HER2 antibody used to treat patients with breast cancer, and a rabbit antibody to folate receptor, along with fluorescently labeled FcBP-ferritin, we demonstrated the specific binding of these complexes to breast cancer cells and folate receptor over-expressing cells, respectively, by fluorescent cell imaging. FcBP-ferritin may be potentially used as modular nanoplatforms for active targeted delivery vehicles or molecular imaging probes with a series of antibodies on demand. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5423 / 5430
页数:8
相关论文
共 44 条
[1]   Ligand-targeted therapeutics in anticancer therapy [J].
Allen, TM .
NATURE REVIEWS CANCER, 2002, 2 (10) :750-763
[2]   Cell-Specific Delivery of Diverse Cargos by Bacteriophage MS2 Virus-like Particles [J].
Ashley, Carlee E. ;
Carnes, Eric C. ;
Phillips, Genevieve K. ;
Durfee, Paul N. ;
Buley, Mekensey D. ;
Lino, Christopher A. ;
Padilla, David P. ;
Phillips, Brandy ;
Carter, Mark B. ;
Willman, Cheryl L. ;
Brinker, C. Jeffrey ;
Caldeira, Jerri do Carmo ;
Chackerian, Bryce ;
Wharton, Walker ;
Peabody, David S. .
ACS NANO, 2011, 5 (07) :5729-5745
[3]   Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging [J].
Bartlett, Derek W. ;
Su, Helen ;
Hildebrandt, Isabel J. ;
Weber, Wolfgang A. ;
Davis, Mark E. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (39) :15549-15554
[4]   Delivering quantum dots to cells: bioconjugated quantum dots for targeted and nonspecific extracellular and intracellular imaging [J].
Biju, Vasudevanpillai ;
Itoh, Tamitake ;
Ishikawa, Mitsuru .
CHEMICAL SOCIETY REVIEWS, 2010, 39 (08) :3031-3056
[5]   Comparison of random and oriented immobilisation of antibody fragments on mixed self-assembled monolayers [J].
Bonroy, Kristien ;
Frederix, Filip ;
Reekmans, Gunter ;
Dewolf, Ellen ;
De Palma, Randy ;
Borghs, Gustaaf ;
Declerck, Paul ;
Goddeeris, Bruno .
JOURNAL OF IMMUNOLOGICAL METHODS, 2006, 312 (1-2) :167-181
[6]   Nanoparticles in cancer therapy and diagnosis [J].
Brigger, I ;
Dubernet, C ;
Couvreur, P .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (05) :631-651
[7]  
Carney Walter P, 2004, Clin Breast Cancer, V5, P105, DOI 10.3816/CBC.2004.n.014
[8]   Improving the efficacy of antibody-based cancer therapies [J].
Carter, P .
NATURE REVIEWS CANCER, 2001, 1 (02) :118-129
[9]   Nanotechnology: Intelligent design to treat complex disease [J].
Couvreur, Patrick ;
Vauthier, Christine .
PHARMACEUTICAL RESEARCH, 2006, 23 (07) :1417-1450
[10]   Comparison of antibody functionality using different immobilization methods [J].
Danczyk, R ;
Krieder, B ;
North, A ;
Webster, T ;
HogenEsch, H ;
Rundell, A .
BIOTECHNOLOGY AND BIOENGINEERING, 2003, 84 (02) :215-223